Evaluation of intra-articular hyaluronan, sodium chondroitin sulfate and N-acetyl-D-glucosamine combination versus saline (0.9% NaCl) for osteoarthritis using an equine model.

The research article evaluates a treatment for osteoarthritis in horses. This treatment involves a combination of hyaluronan, sodium chondroitin sulfate and N-acetyl-D-glucosamine administered directly into the affected joint and is compared against a saline solution.

Objective of the Study

The primary objective of this study was to compare the effectiveness of a compound made of hyaluronan, sodium chondroitin sulfate and N-acetyl-D-glucosamine, and saline (0.9% NaCl) for treating osteoarthritis. Osteoarthritis was artificially induced in one joint of 16 horses, followed by the treatment administered intra-articularly (directly into the joint).

Methodology

• The study was a randomized blinded placebo-controlled trial.
• Osteoarthritis was artificially induced in one carpal (wrist) joint of each horse.
• The horses were divided into two groups: one receiving the compound (PG) treatment and one receiving the placebo (saline).
• All horses received 125 mg of amikacin sulfate (an antibiotic) and 5 mL of physiological saline in the middle carpal joint on study Days 0, 7, 14, and 28. However, the OA-affected joint in the PG group received the PG treatment instead of saline.
• The horses’ condition was regularly evaluated using a variety of methods, including clinical and radiographic examinations, synovial fluid analysis, gross and histological examinations, as well as histochemical and biochemical analyses.

Results and Conclusion

• The use of the PG compound resulted in a transient 16% improvement in clinical pain (measured through lameness scores).
• There was also some evidence of improvement trends in bone proliferation radiographically and in the degree of full thickness articular cartilage erosion seen grossly, when compared to placebo-treated OA-affected joints.
• However, the majority of the outcome parameters were not significantly different from the control group (the group that received the placebo treatment).
• No adverse treatment-related events were observed in any of the horses.
• The findings suggest that the PG compound may have some potential in modifying clinical signs or disease progression of osteoarthritis when administered directly into the affected joint, although the results were not significantly better than the placebo.